Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961945 · ClinicalTrials.gov registry record · NA
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
A NA study of Esophageal Adenocarcinoma and Barrett Esophagus, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 1,550
- Enrollment target
- 9
- Study locations
NCT03961945: Recruiting NA study of Esophageal Adenocarcinoma and Barrett Esophagus, sponsored by Mayo Clinic.
NCT03961945 is a NA study of Esophageal Adenocarcinoma and Barrett Esophagus that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,550 participants, above the 272-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (470% higher). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03961945, a NA study of Esophageal Adenocarcinoma and Barrett Esophagus, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,550 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
Primary Outcome
To measure the positive and negative predictive value of the sponge capsule Barrett's esophagus test in a screening population.
Conditions Studied
Interventions
- DEVICE Sponge Capsule
Study Locations (9)
Minnesota
- Mayo Clinic Health Systems - Austin - Austin
- Mayo Clinic Health Systems - Mankato - Mankato
- Mayo Clinic Rochester - Rochester
Wisconsin
- Mayo Clinic Health System-Eau Claire - Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare - La Crosse
Arizona
- Mayo Clinic Arizona - Scottsdale
Florida
- Mayo Clinic Jacksonville - Jacksonville
New York
- Northwell Health - New Hyde Park
Texas
- Baylor Scott & White Research Institute - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,550 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2030-07-30 |
| Phase | NA |
What NCT03961945 shows while recruiting
NCT03961945 is an interventional study that assigns participants to a tested intervention. Its 1,550 participants enrollment target places it among the larger protocols in the corpus, above the 272-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (470% higher).
The record links to 2 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Sponge Capsule is the first listed.
NCT03961945 lists 9 locations in 6 states (Minnesota, Wisconsin, Arizona).
Frequently Asked Questions
What is clinical trial NCT03961945 about?
NCT03961945 is a clinical study titled "Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma". This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
What is the current status of trial NCT03961945?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,550 participants. The study started on 2021-07-01. Estimated completion is 2030-07-30.
What conditions does trial NCT03961945 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett Esophagus.
What interventions are being tested in trial NCT03961945?
The interventions under investigation include: Sponge Capsule (DEVICE).
Who is sponsoring clinical trial NCT03961945?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03961945 being conducted?
This trial has 9 study locations across Arizona, Florida, Minnesota, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03961945's enrollment target sits among peer trials
1,550 3rd of 43 higher than 41 of 43 other Esophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
RECRUITING · NA
-
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
COMPLETED · NA
-
Esophageal Cytology With FISH in Detecting Esophageal Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
- NCT03435796 · 1,541 participants · Phase 2
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- NCT06881069 · 1,560 participants · NA
Reach Through Equitable Implementation in Utah
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI